1- World Health Organization, Geneva (2016). Global report on diabetes.

2- Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Man CD, Cobelli C, Cline GW, Shulman G, Waldhäusl W & Roden M (2004). Alterations in Postprandial Hepatic Glycogen Metabolism in Type 2 Diabetes. Diabetes, 53(12): 3048-3056.

3- Clemens KK, O’Regan N & Rhee JJ (2019). Diabetes Management in Older Adults With Chronic Kidney Disease. Curr Diab Rep. https://doi.org/10.1007/s11892-019-1128-3.

4- Sprague JE & Arbeláez AM (2011). Glucose Counterregulatory Responses to Hypoglycemia. Pediater Endocrinol Rev 9(1): 463-475.

5- Gharib HM, Abajy MY & Omaren A (2020). Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats.

https://doi.org/10.1016/j.heliyon.2020.e03812.

6- Aronson D & Edelman ER (2016). Coronary artery disease and diabetes mellitus. Heart Failure Clin., 12: 117–133.

7- Balouch GH, Shaikh S, Shah SZA, Devrajani BR, Rajpar N, Shaikh N & Devrajani T (2011). Silent ischaemia in patients with type 2 diabetes mellitus. World Appl Sci J., 13: 213-216.

8- Edwards G, Feletou M & Weston AH (2010). Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Eur J Physiol, 459: 863-879.

9- Brunton LL, Dandan RH & Knollmann BC (2018). Goodman and gilman,s the pharmacological basis of therapeutics. 13th edition.

10- Erkens JA, Klungel OH, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE & Leufkens HG (2002). Use of fluoroquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patient. Eur Heart J., 23: 1557-1579.

11- Absi M, Ghareeb H, Khalil A & Ruegg UT (2012). The Effect of Levofloxacin and Moxifloxacin on Cardiovascular Functions of Rats with Streptozotocin-Induced Diabetes. Diab & Vas Dis Res., 10(1): 65-71.

12- Tamarina NA, Wang Y, Mariotto L, Kuznetsov A, Bond C, Adelman J & Philipson LH (2003). Small-Conductance Calcium-Activated K+ Channels Are Expressed in Pancreatic Islets and Regulate Glucose Responses. Diabetes, 52(8): 2000-2006.

13- Düfer M, Neye Y, Hörth K, Krippeit-Drews P, Hennige A, Widmer H, McClafferty H, Shipston MJ, Häring HU, Ruth P, Drews G (2011). BK channels affect glucose homeostasis and cell viability of murine pancreatic beta cells. Diabetologia, 54(2): 423-432.

14- Zhou Y, Sun P, Wang T, Chen K, Zhu W & Wang H (2015). Inhibition of Calcium Influx Reduces Dysfunction and Apoptosis in Lipotoxic Pancreatic β-Cells via Regulation of Endoplasmic Reticulum Stress. PLoS ONE10(7).

15- Sonkusare S, Palade PT, Marsh JD, Telemaque S, Pesic A & Ruscha NJ (2006). Vascular calcium channels and high blood pressure: Pathophysiology and therapeutic implications. Vascul Pharmacol 44(3): 131-142.

16- Goyal SN, Reddy NM, Patil KR, Nakhate KT, Ojha S, Patil CR & Agrawal YO (2016). Challenges and Issues with Streptozotocin-Induced Diabetes – A Clinically Relevant Animal Model to Understand the Diabetes Pathogenesis and Evaluate Therapeutics. Chemico-Biol Int 244: 49-63.

17- Pramila K & JuliusA (2019). Antihyperglycemic, Antidyslipidemic and Antifibrotic effect of EGCG in STZ – High Fat Diet Induced DCM rats. Research J Pharm and Tech, 12(4).

18- Barrière DA, Noll C, Roussy G, Lizotte F, Kessai A, Kirby K, Belleville K, Beaudet N, Longpré JM, Carpentier AC, Geraldes P & Sarret P (2018). Combination of High-Fat/High-Fructose Diet and Low-Dose Streptozotocin to Model Long-Term Type-2 Diabetes Complications. Sci Rep 8: 424.

19- Qinna NA & Badwan AA (2015). Impact of streptozotocin on altering normal glucose 18 homeostasis during insulin testing in diabetic rats compared to normoglycemic rats. Drug Des 19 Devel 9: 2515–2525.

20- Sun M, Yokoyama M, Ishiwata T & Asano G (1998). Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Pathol., 79(4): 207–222.

21-Gao L & Mann GE (2009). Vascular NAD (P)H oxidase activation in diabetes: a double-edged sword in redox signaling. Cardiovasc Res 82: 9-20.

22- Murillo O, Pachon ME, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Gudiol F & Ariza J (2009). High doses of Levofloxacin vs Moxifloxacin against Staphylococcal Experimental Foreign-Body Infection: The Effect of Higher MIC-Related Pharmacokinetic Parameters on Efficacy. J Infect. 58: 220-226.

23- Sadariya KA, Gothi AK, Patel SD, Bhavsar SK & Thaker AM (2010). Safety of Moxifloxacin Following Repeated Intramuscular Administration in Wistar Rats. Veterinary World 3(10): 449-452.

24- Langtry HD & Lamb HM (1999). Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 56(3): 487-515.

25- Rawi SM, Mourad IM, Arafa NMS & Alazabi NI (2011). Effect of Ciprofloxacin and Levofloxacin on Some Oxidative Stress Parameters in Brain Regions of Male Albino Rats. African J Pharm Pharmacol., 5(16): 1888-1897.

26- Olsen KM, Gentry-Nielsen M, Yue M, Snitily MU, Preheim LC (2006). Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia. Antimicrobial Agents and Chemotherapy. 50: 210-219.

27- Braslasu ED, Bradatan C, Cornila M, Savulescu I, Cojmaleata R & Braslasu MC (2007). Normal blood glucose in white wistar rat and its changes following anesthesia. LUCRĂRI ṢTIINłIFICE MEDICINĂ VETERINARĂ. 120-123.

28- Chang JS, You YH, Park SY, Kim JW, Kim HS, Kun-Ho Yoon KH & Jae-Hyoung Cho JH (2013). Pattern of Stress-Induced Hyperglycemia according to Type of Diabetes: A Predator Stress Model. Diab Metab J 37: 475-483.

29- Bancroft JD & Cook HC (1994). Manual of histological techniques and their diagnostic application, second edition, edinburgh, churchill livingstone.

30- Jia G, Durante W & Sowers JR (2016). Endothelium-Derived Hyperpolarizing Factors: A Potential Therapeutic Target for Vascular Dysfunction in Obesity and Insulin Resistance. Diabetes 65(8): 2118-2120.

31- Girault A, Haelters JP, Potier-Cartereau M, Chantôme A, Jaffrès PA,Bougnoux P, Joulin V & Vandier C (2012). Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches. Curr Med Chem., 19: 697-713.

32- Robertson RP, Harmon J, Tran PO, Tanaka Y & Takahashi H (2003). Glucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection. Diabetes 52(3): 581-587.

33- Marshall WJ & Bangert SK (2014). Clinical biochemistry metabolic and clinical aspects, third edition.

34- Kreider KE, Pereira K & Padilla BI (2017). Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes. Diabetes Ther 8(6): 1427-1435.

35- Wang HJ, Jin YX, Shen W, Neng J, Wu T, Li YJ & Fu ZW (2007). Low dose streptozotocin (STZ) combined with high energy intake can effectively induce type 2 diabetes through altering the related gene expression. Asia Pac J Clin Nutr 16: 412-417.

36- Brodeur MR, Bouvet C, Bouchard S, Moreau S, Leblond J, deBlois D & Moreau P (2014). Reduction of Advanced-Glycation End Products Levels and Inhibition of RAGE Signaling Decreases Rat Vascular Calcification Induced by Diabetes. PLoS One 9:e85922.

37- Zhao L, Wang Y, Ma X, Wang Y & Deng X (2013). Oxidative stress impairs IKCa- and SKCa-mediated vasodilatation in mesenteric arteries from diabetic rats. Nan Fang Yi Ke Da Xue Xue Bao 33(7): 939-944.

38- Senatus LM & Schmidt AM (2017). The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases. DOI:10.3389/fgene.2017.00187.

39- Sullivan MG (2018). Fluoroquinolones can cause fatal hypoglycemia, FDA warns. MDedge News.

40- Ishiwata Y, Itoga Y & Yasuhara M (2006). Effects of levofloxacin on serum glucose concentration in rats. Eur J Pharmacol 551: 168-174.

41- Kabbara WK, Ramadan WH, Rahbany P & Al-Natour S (2015). Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia. Ther Clin Risk Manag. 11: 639–647. doi:10.2147/TCRM.S81280.

42- Saraya A, Yokokura M, Gonoi T & Seino S (2004). Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitive K+ channels. Eur J Pharmacol., 497: 111-117.

43- Hori S., kizu J. & kawamura M. (2006). Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice. J Infect Chemother, 12: 109-111.

44- Gavin JR., Kubin R., Choudhri S., Kubitza D., Himmel H., Gross R. & Meyer JM (2004). Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf., 27: 671-686.

45- Kelesidis T & Canseco E (2009). Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely used antibiotic. Am J Med., 122: 3-4.

46- Berhe A., russom M., bahran F. & Hugos G. (2019). Ciprofloxacin and risk of hypoglycemia in non- diabetic patients. J Med Case Reports, 13: 142.

47- Watson MR, Ward CT, Prabhaker A, Fiza B & Moll V (2019). Successful Use of Octreotide Therapy for Refractory Levofloxacin-Induced Hypoglycemia: A Case Report and Literature Review. https://doi.org/10.1155/2019/3560608.

48- Parilo MA (2002). Gatifloxacin-Associated Hypoglycemia. J Pharm Technol., 18: 319-20.

49- Vallurupalli S, Huesmann G, Gregory J & Jakoby MG (2008). Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med., 25: 856-859.

50- Kapoor R, Blum D, Batra A, Varma N, Lakshmi K, Basak P & Jesmajian S (2012). Life-threatening hypoglycemia with moxifloxacin in a dialysis patient. J Clin Pharmacol., 52: 269-271.

51- Singal DK, Mittal A & Prakash A (2013). Recurrent episodes of hypoglycemia induced by moxifloxacin. Indian Journal of Pharmacology, 45(3): 301–302.

52- Mandavia DR, Virpariya MM, Patel TK & Tripathi CB (2012). Moxifloxacin-induced Hypoglycemia in a Non-diabetic Patient. Current Drug Safety, 7: 183-185.

53- Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY & Lai MS (2013). Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis., 57(7): 971-980.

54- Ishiwata Y & Yasuhara M (2010). Gatifloxacin-induced histamine release and hyperglycemia in rats. Euro J Pharmacol., 645: 192-197.

55- Ishiwata Y, Takahashi Y, Nagata M & Yasuhara M (2013). Effects of Moxifloxacin on Serum Glucose Concentrations in Rats. Biol Pharm Bull., 36(4): 686–690.

56- Nagai M, Nagata S, Yamagishi N, Satoh H & Furuhama K (2010). Clinicopathological aspect of dysglycemia in native and diabetic rats induced by the fluoroquinolone antibacterial gatifloxacin. Toxicology, 72: 567-537.

57- Yamada C, Nagashima K, Takahashi A, Ueno H, Kawasaki Y, Yamada Y, Seino Y & Inagaki N (2006). Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol., 553: 67-72.

58- Yabe K, Yamamoto Y, Suzuki T, Takada S & Mori K (2018). Functional and Morphological Characteristics of Pancreatic Islet Lesions Induced by Quinolone Antimicrobial Agent Gatifloxacin in Rats. Toxicologic Pathology, 47(1):019262331-880906. DOI: 10.1177/0192623318809062.

59- Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T & Donath MY (2005). Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab., 90: 501–506.

60- Nichols CG & Remedi MS (2012). The diabetic β-cell: hyperstimulated vs. hyperexcited. Diabetes Obes Metab., 14(03): 129-135.

61- Ghaly H, Kriete C, Sahin S, Pfloger A, Holzgrabe U, Zunkler BJ & Rustenbeck I (2009). The insulinotropic effect of fluoroquinolones. Biochem Pharmacol., 77:1040-1052. doi:10.1016/j.bcp. 2008.11. 019.

62- Gürpinar AN, Balkan E, Kiliç N, Kiriştioğlu I & Doğruyol H (1997). The effects of a fluoroquinolone on the growth and development of infants. J Int Med Res., 25(5): 302-306.

63- Jason M Sansone, Norman J. Wilsman, Ellen M. Leiferman, James Conway, Paul Hutson, Kenneth J. Noonan (2009). The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop., 29(2): 189-195.

64- De Magalhaes DA, Kume WT, Correita FS, Queiroz TS, Allebrandt Neto EW, Dos Santos MP, Kawashita NH & Franca SA (2019). High-fat diet and streptozotocin in the induction of type 2 diabetes mellitus: a new proposal. An Acad Bras Cienc., 91(1): e20180314. http://dx.doi.org/10.1590/0001-3765201920180314.

65- Guo X, Wang Y, Wang K, Ji B, & Zhou F (2018). Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection. J Zhejiang Univ Sci B., 19(7): 559–569.

66- Wulff H, Castle NA (2012). Therapeutic potential of KCa3.1 blockers: an overview of recent advances, and promising trends. Expert Rev Clin Pharmacol., 3(3): 385–396.

67- Jacobson D & Shyng SL (2019). Ion Channels of the Islets in Type 2 Diabetes. J Mol Biol., 432(5): 1326-1346.

68- More AS, Mishra JS, Hankins GDV, Yallampalli C & Sathishkumar K (2015). Enalapril Normalizes Endothelium-Derived Hyperpolarizing Factor-Mediated Relaxation in Mesenteric Artery of Adult Hypertensive Rats Prenatally Exposed to Testosterone. Biol Reprod., 92(6): 155.

69- Diabetes Care (2020). https://doi.org/10.2337/dc20-Sint.

70- Li-Mei Zhao, Yan Wang, Yong Yang, Rong Guo, Nan-Ping Wang, and Xiu-Ling Deng (2014). Metformin Restores Intermediate-Conductance Calcium-Activated K+ channel– and Small-Conductance Calcium-Activated K+ channel–Mediated Vasodilatation Impaired by Advanced Glycation End Products in Rat Mesenteric Artery. Mol Pharmacol., 86: 580–591.

71-       Fu X, Pan Y, Cao Q, Li B, Wang S, Du H, Duan N & Li X (2018). Metformin restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats. BMC Cardiovasc Disord., 18(1): 63.